Albert Bourla

“I mean, very few comments in the beginning. I think that Pfizer is in a good place right now. We had three serious headwinds in 2025 that I think we resolved all of them in a quite satisfactory way.”

“We had another strong quarter of execution, driving continuous strategic progress. Our revenues and adjusted, diluted EPS in the second quarter, once more exceeded expectations.”

“And that we did despite the fact that we were reducing cost dramatically. And we were able to reduce cost dramatically because we employed AI and very targeted transformational things of changing the business.”

“Pfizer has capabilities that basically none of the others have to that degree. We have probably the largest manufacturing network in the world and the capabilities of its network were able to be demonstrated in COVID.”

“In the first quarter, we exceeded expectations for both total revenues and adjusted diluted earnings per se.”